What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Prostate cancer, Internal medicine, Cancer biomarkers, Oncology and Abiraterone acetate.
Prostate cancer and Docetaxel are commonly linked in his work.
Johann S. de Bono interconnects Endocrinology and Surgery in the investigation of issues within Internal medicine.
His work carried out in the field of Cancer biomarkers brings together such families of science as Cancer research, Prostate, Pharmacology and Circulating tumor cell.
His Oncology research incorporates themes from Clinical trial, Neoplasm, Immunology, Prostate-specific antigen and Cohort.
His Abiraterone acetate research is multidisciplinary, incorporating perspectives in Androgen and Urology.
His most cited work include:
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (3027 citations)
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy (2853 citations)
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers (2735 citations)
What are the main themes of his work throughout his whole career to date?
Johann S. de Bono mainly investigates Internal medicine, Prostate cancer, Oncology, Cancer biomarkers and Cancer research.
His Internal medicine study frequently draws connections between adjacent fields such as Surgery.
His work on Prostate cancer is being expanded to include thematically relevant topics such as Docetaxel.
Johann S. de Bono works mostly in the field of Oncology, limiting it down to topics relating to Prednisone and, in certain cases, Placebo, as a part of the same area of interest.
His study looks at the relationship between Cancer biomarkers and fields such as Pharmacology, as well as how they intersect with chemical problems.
His research integrates issues of Homologous recombination, Prostate and DNA repair in his study of Cancer research.
He most often published in these fields:
- Internal medicine (68.48%)
- Prostate cancer (67.44%)
- Oncology (55.62%)
What were the highlights of his more recent work (between 2019-2021)?
- Prostate cancer (67.44%)
- Internal medicine (68.48%)
- Oncology (55.62%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Cancer research and Castration resistant.
His study in Prostate cancer is interdisciplinary in nature, drawing from both Prostate and Docetaxel.
Internal medicine connects with themes related to Gastroenterology in his study.
His biological study spans a wide range of topics, including Cabazitaxel, Abiraterone, Olaparib, Hazard ratio and Biomarker.
Johann S. de Bono combines subjects such as Synthetic lethality, DNA damage, Small molecule, Bromodomain and Androgen receptor with his study of Cancer research.
As a part of the same scientific family, Johann S. de Bono mostly works in the field of Enzalutamide, focusing on Abiraterone acetate and, on occasion, Prostate-specific antigen, Cohort study and Proportional hazards model.
Between 2019 and 2021, his most popular works were:
- Olaparib for metastatic castration-resistant prostate cancer (222 citations)
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. (135 citations)
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. (116 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Cancer research and Cancer.
Johann S. de Bono has researched Prostate cancer in several fields, including Phases of clinical research, DNA repair and PTEN.
As part of his studies on Internal medicine, he frequently links adjacent subjects like Gastroenterology.
The study incorporates disciplines such as Olaparib, Hazard ratio, Confidence interval and Docetaxel in addition to Oncology.
His Confidence interval study combines topics from a wide range of disciplines, such as Cabozantinib, Mitoxantrone, Abiraterone acetate, Proportional hazards model and Prostate-specific antigen.
His work deals with themes such as Synthetic lethality, Prostate, DNA damage and Androgen receptor, which intersect with Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
